Last reviewed · How we verify

NCT04136379

Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD

Completed Last updated 3 November 2022
What this trial tests

trial testing INR monitoring using a CoaguChek POC device in Congenital Heart Disease in 18 participants. Completed in 31 October 2021.

Timeline
30 September 2019
Primary endpoint
31 October 2021
31 October 2021

Quick facts

Lead sponsorUniversity of Ulster
StatusCompleted
Study typeOBSERVATIONAL
Enrollment18
Start date30 September 2019
Primary completion31 October 2021
Estimated completion31 October 2021
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Ulster

Who can join

14 and older, any sex, with Congenital Heart Disease or Congenital Heart Defect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Summary: Congenital heart disease (CHD) is the most prevalent form of birth defect with a global rate of 1.35 million newborns born with CHD annually. Patients with CHD have an increased risk of cerebrovascular accident (CVA) compared to age-matched control populations. Anticoagulation with warfarin is the mainstay of antithrombotic treatment in these patients and requires frequent monitoring of the International Normalized Ratio (INR). The CoaguChek monitor is a point of care device that enables patients to self-monitor and manage their INR without the need to attend a warfarin clinic. The aim of this study is to compare the efficacy and outcomes of standard clinic management and home management of INR in patients with CHD. Analysis of time in therapeutic range (TTR), INR variability, major and minor bleeding events, incidence of CVA and other thrombotic events will be undertaken. Original Hypothesis: There will be a difference in the proportion of time that patients spend in their therapeutic range and the amount of adverse events that occur between those who use a CoaguChek monitor and those who use standard clinic monitoring of their INR. The primary outcome will be time in therapeutic range (TTR). Secondary outcomes will be INR variability, minor / major bleeding complications and thromboembolic events.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Congenital Heart Disease

Currently open trials in the same condition.

Other University of Ulster trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04136379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing